| Administration route |
intravitreal injection |
| Dosage |
1.5 mg |
| Pts |
322 |
| Age |
Adult, Older_Adult |
| Outcome |
The primary efficacy endpoint is the mean change in visual acuity (ETDRS letters) measured at baseline and at the month 12 visit. Higher ETDRS letters represents higher vision and a higher change in ETDRS letters represents better functioning. Mean (Standard Error) = 9.42(0.85) |
| Adverse reactions |
7/322(All-cause mortality); 58/322(Blood and lymphatic system disorders; Cardiac disorders; Eye disorders; Gastrointestinal disorders; General disorders; Infections and infestations; Injury, poisoning and procedural complications; Musculoskeletal and connective tissue disorders; Neoplasms benign, malignant and unspecified, incl cysts and polyps; Nervous system disorders; Psychiatric disorders; Renal and urinary disorders; Renal and urinary disorders; Respiratory, thoracic and mediastinal disorders) |
|